Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA (March 2006). Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol.47 (3): 493–9. PMID16633095. DOI: 10.1097/01.fjc.0000211732.76668.d2.
Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (December 2006). Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J. Cardiovasc. Pharmacol.48 (6): 314–9. PMID17204911. DOI: 10.1097/01.fjc.0000250077.07702.23.
Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N (May 2000). Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur. J. Pharmacol.395 (3): 217–24. PMID10812052. DOI: 10.1016/S0014-2999(00)00098-4.
Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA (March 2006). Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol.47 (3): 493–9. PMID16633095. DOI: 10.1097/01.fjc.0000211732.76668.d2.
Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (December 2006). Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J. Cardiovasc. Pharmacol.48 (6): 314–9. PMID17204911. DOI: 10.1097/01.fjc.0000250077.07702.23.
Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N (May 2000). Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur. J. Pharmacol.395 (3): 217–24. PMID10812052. DOI: 10.1016/S0014-2999(00)00098-4.